Telomir Pharmaceuticals Closes TELI Acquisition, Secures Global Rights to Telomir-1

Telomir Pharmaceuticals (NASDAQ: TELO) announced the closing of its acquisition of TELI Pharmaceuticals, Inc., establishing the company as the sole global rights holder of Telomir-1 (Telomir-Zn) and eliminating prior geographic fragmentation of the asset. The transaction, approved by shareholders in March, includes $1.0 million in funding at closing and up to an additional $4.0 million in milestone-based contributions tied to clinical development progress.

The company said the acquisition strengthens its position as it advances Telomir-Zn toward the clinic following a recent IND submission for the treatment of advanced and metastatic triple-negative breast cancer, with plans to initiate a Phase 1/2 trial upon regulatory clearance while retaining flexibility for potential global partnerships. This consolidation is critical because it removes previous geographical restrictions, allowing Telomir to fully control development and commercialization strategies worldwide.

Telomir Pharmaceuticals is a preclinical-stage biotechnology company developing small-molecule therapeutics designed to target fundamental epigenetic and metabolic mechanisms implicated in cancer, aging, and degenerative disease. The company’s lead program, Telomir-1 (Telomir-Zn), has demonstrated activity in preclinical studies involving modulation of intracellular metal homeostasis, redox balance, epigenetically regulated gene expression, mitochondrial function, and genomic stability.

The implications of this acquisition are significant for the company’s pipeline. By securing global rights, Telomir can streamline regulatory processes, avoid fragmented partnership negotiations, and retain full value from any future licensing deals. The milestone-based funding structure also aligns financial incentives with clinical progress, potentially accelerating development without diluting shareholder equity upfront.

For investors, the move signals a strategic focus on advancing Telomir-1 through key clinical milestones. The recent IND submission for triple-negative breast cancer—a notoriously difficult-to-treat indication—positions the company to address a high unmet medical need. Success in early trials could unlock substantial value, given the limited treatment options for advanced breast cancer patients.

However, the company remains preclinical, and risks associated with clinical trials, regulatory approvals, and commercialization are inherent. The acquisition also requires successful execution of the development plan to trigger the additional $4.0 million in funding, which may pose financial pressure if milestones are delayed.

Telomir Pharmaceuticals continues to evaluate potential global partnerships, but the consolidated rights provide flexibility to retain exclusivity or selectively collaborate. The company’s focus on epigenetic and metabolic mechanisms differentiates it from competitors targeting downstream pathways.

For more details, the full press release is available at https://ibn.fm/DcY4o. Additional updates on Telomir Pharmaceuticals are accessible in the company’s newsroom at https://ibn.fm/TELO.